Tivozanib: Practical implications for renal cell carcinoma and other solid tumors

Drugs of Today

Volumn 49, Issue 5, 2013, Pages 303-315

  Berge, E M ^a   Bowles, D W ^a,b   Flaig, T W ^a   Lam, E T ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

TIVo; Tivozanib; VEgFr 1 (FLT 1) inhibitors; VEgFr 2 (FLK 1 KDr) inhibitors; VEgFr 3 (FLT 4) inhibitors

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB ALANINATE; CAPECITABINE; CEDIRANIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLT3 LIGAND; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; LINIFANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; REGORAFENIB; SORAFENIB; TIVOZANIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BILE DUCT CARCINOMA; BREAST CANCER; BREAST METASTASIS; COLORECTAL CARCINOMA; COMPRESSION FRACTURE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG URINE LEVEL; ENDOMETRIUM CANCER; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; IC 50; KIDNEY CARCINOMA; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; METASTATIC COLORECTAL CANCER; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; SARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL VEIN ENDOTHELIAL CELL;

TIVO; TIVOZANIB; VEGFR-1 (FLT-1) INHIBITORS; VEGFR-2 (FLK-1/KDR) INHIBITORS; VEGFR-3 (FLT-4) INHIBITORS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84878710646     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.5.1960218     Document Type: Article

References (86)

1. Motzer, R.J., Mazumdar, M., Bacik, J., Berg, W., amsterdam, A., Ferrara, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin oncol 1999, 17(8): 2530-40. (Pubitemid 29368255)
2. Siegel, R., Ward, E., Brawley, O., Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Ca Cancer J Clin 2011, 61(4): 212-36.
3. Janzen, N.K., Kim, H.L., Figlin, R.A., Belldegrun, A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin north am 2003, 30(4): 843-52. (Pubitemid 37485197)
4. Motzer, R.J., hutson, T.E., Tomczak, P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin oncol 2009, 27(22): 3584-90.
5. Klapper, J.A., Downey, S.G., Smith, F.O. et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008, 113(2): 293-301.
6. negrier, S., Escudier, B., Lasset, C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. n Engl J Med 1998, 338(18): 1272-8. (Pubitemid 28216581)
7. Kaelin, W.G., Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115(10, Suppl.): 2262-72.
8. nickerson, M.L., Jaeger, E., Shi, Y. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer res 2008, 14(15): 4726-34.
9. Kim, W.Y., Kaelin, W.G. Role of VHL gene mutation in human cancer. J Clin oncol 2004, 22(24): 4991-5004. (Pubitemid 46646218)
10. Semenza, G.L. Targeting HIF-1 for cancer therapy. nat rev Cancer 2003, 3(10): 721-32. (Pubitemid 37328811)
11. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. n Engl J Med 2007, 356(2): 125-34. (Pubitemid 46089673)
12. Sternberg, C.N., Davis, I.D., Mardiak, J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin oncol 2010, 28(6): 1061-8.
13. rini, B.I., Escudier, B., Tomczak, P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378(9807): 1931-9.
14. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. nature 2000, 407(6801): 249-57.
15. Escudier, B.J., porta, C., Bono, P. et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin oncol [48th annu Meet am Soc Clin oncol (aSCo) (June 1-5, Chicago) 2012] 2012, 30(18, Suppl.): abst Cra4502.
16. De Bock, K., Mazzone, M., Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat rev Clin oncol 2011, 8(7): 393-404.
17. Llovet, J.M., ricci, S., Mazzaferro, V. et al. Sorafenib in advanced hepatocellular carcinoma. n Engl J Med 2008, 359(4): 378-90.
18. Demetri, G.D., van oosterom, A.T., garrett, C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544): 1329-38. (Pubitemid 44528723)
19. van der graaf, W.T., Blay, J.Y., Chawla, S.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379(9829): 1879-86.
20. nakamura, K., Taguchi, E., Miura, T. et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer res 2006, 66(18): 9134-42. (Pubitemid 44521133)
21. Taguchi, E., nakamura, K., Miura, T., Shibuya, M., Isoe, T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci 2008, 99(3): 623-30. (Pubitemid 351228583)
22. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer res 2004, 64(19): 7099-109. (Pubitemid 39331023)
23. Mendel, D.B., Laird, A.D., Xin, X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer res 2003, 9(1): 327-37. (Pubitemid 36109749)
24. Kumar, R., Knick, V.B., rudolph, S.K. et al. Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(7): 2012-21. (Pubitemid 47052491)
25. Chow, L.Q., Eckhardt, S.G. Sunitinib: from rational design to clinical efficacy. J Clin oncol 2007, 25(7): 884-96. (Pubitemid 350002890)
26. Cotreau, M.M., hale, C.L., Jacobson, L. et al. Absorption, metabolism, and excretion of [14C]-tivozanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in healthy male participants: A phase I, open-label, mass-balance study. Clin pharmacol Drug Dev 2012, 1(3): 102-9.
27. Eskens, F.A., de Jonge, M.J., Bhargava, P. et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer res 2011, 17(22): 7156-63.
28. A single center, open-label, randomized, two-period crossover food effect study of single doses of tivozanib (AV-951) in healthy subjects (NCT01316848). Clinical Trials.gov Web site, accessed april 29, 2013.
29. A phase 1 study to evaluate the effect of ketoconazole on the pharmacokinetics of tivozanib in healthy subjects (NCT01363778). Clinical Trials.gov Web site, accessed april 29, 2013.
30. A phase 1 study to evaluate the effect of rifampin on the pharmacokinetics of tivozanib in healthy subjects (NCT01363804). Clinical Trials.gov Web site, accessed april 29, 2013.
31. Eisenhauer, E.A., Therasse, P., Bogaerts, J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2): 228-47.
32. Kabbinavar, F.F., Srinivas, S., hauke, R.J. et al. A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin oncol [genitourin Cancers Symp (Feb 17-19, orlando) 2011] 2011, 29(7, Suppl.): abst 330.
33. nosov, D.A., Esteves, B., Lipatov, O.N. et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin oncol 2012, 30(14): 1678-85.
34. Bhargava, P., Esteves, B., al-adhami, M. et al. Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC). J Clin oncol [genitourin Cancers Symp (Feb 17-19, orlando) 2011] 2011, 29(7, Suppl.): abst 327.
35. Motzer, R.J., nosov, D., Eisen, T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin oncol [48th annu Meet am Soc Clin oncol (aSCo) (June 1-5, Chicago) 2012] 2012, 30(15, Suppl.): abst 4501.
36. rini, B.I., Cohen, D.P., Lu, D.R. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J natl Cancer Inst 2011, 103(9): 763-73.
37. Cella, D., Ivanescu, C., Skaltsa, K. et al. Treatment benefit of tivozanib hydrochloride versus sorafenib on health-related quality of life (HRQoL) among patients (pts) with advanced/metastatic renal cell carcinoma (mRCC): TIVO-1 study results. J Clin oncol [genitourin Cancers Symp (Feb 14-16, orlando) 2013] 2013, 31(6, Suppl.): abst 355.
38. Motzer, R.J., Eisen, T., hutson, T.E. et al. Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. J Clin oncol [genitourin Cancers Symp (Feb 14-16, orlando) 2013] 2013, 31(6, Suppl.): abst 350.
39. Eskens, F., oldenhuis, C.N., Bhargava, P. et al. A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. J Clin oncol [gastrointest Cancers Symp (Feb 17-19, orlando) 2011] 2011, 29(4, Suppl.): abst 549.
40. Eskens, F., oldenhuis, C.N., Loos, W.J. et al. Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. J Clin oncol [48th annu Meet am Soc Clin oncol (aSCo) (June 1-5, Chicago) 2012] 2012, 30(15, Suppl.): abst 4132.
41. A study combining mFOLFOX6 with tivozanib or bevacizumab in patients with metastatic colorectal cancer as first line therapy (NCT01478594). Clinical Trials.gov Web site, accessed april 29, 2013.
42. A trial of tivozanib (AV-951) in combination with capecitabine (Xeloda®) in subjects with advanced solid tumors (NCT01306630). Clinical Trials.gov Web site, accessed april 29, 2013.
43. Wolpin, B.M., ng, K., Zhu, A.X. et al. Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer. J Clin oncol [gastrointest Cancers Symp (Jan 19-21, San Francisco) 2012] 2012, 30(4, Suppl.): abst 560.
44. Mayer, E.L., Scheulen, M.E., Beckman, J. et al. Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study. J Clin oncol [47th annu Meet am Soc Clin oncol (aSCo) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): abst 1092.
45. AVEO and Astellas announce initiation of patient enrollment in phase 2 trial of tivozanib in combination with paclitaxel in patients with advanced triple negative breast cancer [news release]. aVEo pharmaceuticals, December 3, 2012. http://investor.aveooncology.com/phoenix.zhtml?c=21965 1&p=irol-newsarticle&ID=1763550&highlight=. accessed January 12, 2013.
46. AVEO and Astellas announce FDA acceptance of NDA filing for tivozanib for the treatment of advanced renal cell carcinoma [news release]. aVEo oncology, november 28, 2012. accessed January 12, 2013.
47. AVEO reports second quarter 2012 financial results [news release]. aVEo pharmaceuticals, august 2, 2012. http://investor.aveooncology.com/phoenix.zhtml? c=21965 1&p=irol-newsarticle&ID=1721417&highlight=. accessed January 12, 2013.
48. halabi, S., rini, B.I., Stadler, W.M., Small, E.J. Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). 46th annu Meet am Soc Clin oncol (aSCo) (June 4-8, Chicago) 2010, 28(15, Suppl.): abst 4525.
49. Escudier, B., Steelman, L., Cesic, D., Berkenblit, A. Patient preference for tivozanib hydrochloride or suntinib in the treatment of metastatic renal cell carcinoma (mRCC): TAURUS study. Eur Soc Med oncol (ESMo) Sci Edu Conf (Sept 28-oct 2, Vienna) 2012, abst 892Tip.
50. rugo, H.S., herbst, R.S., Liu, G. et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin oncol 2005, 23(24): 5474-83.
51. hu-Lowe, D.D., Zou, H.Y., grazzini, M.L. et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer res 2008, 14(22): 7272-83.
52. Sonpavde, G., hutson, T.E., rini, B.I. Axitinib for renal cell carcinoma. Expert opin Investig Drugs 2008, 17(5): 741-8. (Pubitemid 351843617)
53. Szmit, S., Zaborowska, M., Wasko-grabowska, A. et al. Cardiovascular comorbidities for prediction of progressionfree survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood press res 2012, 35(6): 468-76.
54. rini, B.I., Schiller, J.H., Fruehauf, J.P. et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer res 2011, 17(11): 3841-9.
55. Tomita, Y., Uemura, H., Fujimoto, H. et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011, 47(17): 2592-602.
56. Clemons, J., gao, D., naam, M., Breaker, K., garfield, D., Flaig, T.W. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin genitourin Cancer 2012, 10(4): 225-31.
57. Deprimo, S.E., Bello, C.L., Smeraglia, J. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5: 32.
58. Tran, H.T., Liu, Y., Zurita, A.J. et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet oncol 2012, 13(8): 827-37.
59. Xu, C.F., Bing, N.X., Ball, H.A. et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin oncol 2011, 29(18): 2557-64.
60. perez-gracia, J.L., prior, C., guillen-grima, F. et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009, 101(11): 1876-83.
61. Kontovinis, L.F., papazisis, K.T., Touplikioti, P., andreadis, C., Mouratidou, D., Kortsaris, A.H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9: 82.
62. hutson, T.E., rathmell, K., hudes, G.R. et al. A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). J Clin oncol [48th annu Meet am Soc Clin oncol (aSCo) (June 1-5, Chicago) 2012] 2012, 30(15, Suppl.): abst TpS4686.
63. robinson, M.O., Lin, J., Feng, B. et al. Correlation of a tivozanib response biomarker identified in a preclinical model with clinical activity in a phase II study in renal cell carcinoma (RCC). J Clin oncol [46th annu Meet am Soc Clin oncol (aSCo) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): abst e13564.
64. robinson, M.O., Feng, B., nicoletti, R. et al. Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride. J Clin oncol [genitourin Cancers Symp (Feb 14-16, orlando) 2013] 2013, 31(6, Suppl.): abst 361.
65. robert, N.J., Saleh, M.N., paul, D. et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011, 11(2): 82-92.
66. reardon, D.A., Vredenburgh, J.J., Coan, A. et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J neurooncol 2011, 105(3): 621-7.
67. Camidge, D.R., Blais, N., Jonker, D.J. et al. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother pharmacol 2012, 71(2): 307-19.
68. azad, N.S., posadas, E.M., Kwitkowski, V.E. et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin oncol 2008, 26(22): 3709-14.
69. Socinski, M.A., Scappaticci, F.A., Samant, M., Kolb, M.M., Kozloff, M.F. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac oncol 2010, 5(3): 354-60.
70. rini, B.I., garcia, J.A., Cooney, M.M. et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer res 2009, 15(19): 6277-83.
71. Lee, E.Q., Kuhn, J., Lamborn, K.R. et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. neuro oncol 2012, 14(12): 1511-8.
72. paz-ares, L.G., Biesma, B., heigener, D. et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin oncol 2012, 30(25): 3084-92.
73. Tan, A.R., Dowlati, A., Jones, S.F. et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. oncologist 2010, 15(12): 1253-61.
74. plummer, R., Madi, A., Jeffels, M. et al. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother pharmacol 2013, 71(1): 93-101.
75. Martin, L.P., Kozloff, M.F., herbst, R.S. et al. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer 2012, 107(8): 1268-76.
76. Kozloff, M.F., Martin, L.P., Krzakowski, M. et al. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer 2012, 107(8): 1277-85.
77. Sharma, S., abhyankar, V., Burgess, R.E. et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ann oncol 2010, 21(2): 297-304.
78. U.S. Food and Drug administration. Approved drugs: Axitinib. http://www.fda.gov/Drugs/InformationonDrugs/approvedDrugs/ucm289439.htm. accessed January 16, 2013.
79. Jonker, D.J., rosen, L.S., Sawyer, M.B. et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. ann oncol 2011, 22(6): 1413-9.
80. Angevin, E., Grunwald, V., Ravaud, A. et al. A phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin oncol [47th annu Meet am Soc Clin oncol (aSCo) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): abst 4551.
81. Mross, K., Frost, A., Steinbild, S. et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer res 2012, 18(9): 2658-67.
82. Wong, C.I., Koh, T.S., Soo, R. et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin oncol 2009, 27(28): 4718-26.
83. Drevs, J., Siegert, P., Medinger, M. et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin oncol 2007, 25(21): 3045-54. (Pubitemid 47218051)
84. Motzer, R.J., Escudier, B., oudard, S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637): 449-56.
85. Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. n Engl J Med 2012, 366(26): 2455-65.
86. Topalian, S.L., hodi, F.S., Brahmer, J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. n Engl J Med 2012, 366(26): 2443-54.